Imugene RMT move
IMUGENE has announced commercial development plans for its first receptor mimic technology product.
The first product will be used to treat colibacillosis in pigs, a disease caused by e-coli bacteria.
Imugene managing director Warwick Lamb said the RMT platform technology allowed the company to broaden the range of diseases it could treat.
The product, a biological oral treatment, has a shorter registration process than chemical treatments.
Imugene also plans to use existing biological manufacturing facilities to produce the treatment, rather than building its own.